Background
Warner-Lambert held U.S. Patent 5,084,479 covering a method of treating neurodegenerative diseases — including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, ALS, and stroke — using gabapentin. Gabapentin was the active ingredient in Warner-Lambert’s drug Neurontin, which had FDA approval for treating epilepsy (partial seizures). The epilepsy-method patent was separately held and was expiring. The neurodegenerative-disease patent (the ‘479 patent) claimed an unapproved use — treating neurodegenerative diseases with gabapentin was not an FDA-approved indication for Neurontin.
Apotex filed an Abbreviated New Drug Application (ANDA) under the Hatch-Waxman Act seeking FDA approval to sell a generic form of gabapentin upon the expiration of the epilepsy-method patent. Apotex’s proposed generic label would cover only the FDA-approved epilepsy indication, not neurodegenerative diseases. Warner-Lambert sued, arguing that Apotex’s ANDA filing infringed the ‘479 neurodegenerative-disease patent under 35 U.S.C. § 271(e)(2), and that Apotex would inevitably induce infringement because some physicians would prescribe generic gabapentin for off-label neurodegenerative-disease treatment.
The district court granted Apotex summary judgment of noninfringement, and Warner-Lambert appealed.
The Court’s Holding
The Federal Circuit affirmed. The court held that a filing under § 271(e)(2)(A) constitutes an act of infringement only when the ANDA applicant seeks approval to sell a drug for a use that is claimed in an unexpired patent. Apotex sought approval only for the FDA-approved epilepsy indication — it was not seeking approval to sell gabapentin for treating neurodegenerative diseases. Therefore, the ANDA filing did not constitute infringement of Warner-Lambert’s neurodegenerative-disease patent.
On induced infringement under § 271(b), the court likewise rejected Warner-Lambert’s claims. Mere knowledge that some physicians might prescribe a generic drug for off-label uses — without any affirmative action by the generic company to encourage those uses — does not constitute inducement. For induced infringement, specific intent and affirmative action to promote the infringing use are required. Apotex’s label covered only the epilepsy indication; the fact that gabapentin was already known and might be used off-label did not make Apotex’s ANDA an act of inducement.
Key Takeaways
- Under 35 U.S.C. § 271(e)(2), an ANDA filing is an artificial act of infringement only with respect to uses claimed in unexpired patents; it does not infringe patents on unapproved off-label uses of the drug.
- A generic manufacturer whose ANDA label covers only FDA-approved uses does not induce infringement of patents on unapproved uses simply because physicians might prescribe the drug off-label.
- Induced infringement requires specific intent and affirmative conduct to encourage the infringing use; knowledge of possible future infringement is not enough.
- Innovator pharmaceutical companies cannot use method-of-use patents on unapproved indications to block generic entry for approved uses of the same drug.
- This ruling shaped the practice of “skinny labeling” — the ability of generic manufacturers to carve out patented uses from their labels to avoid infringement while still entering the market.
Why It Matters
Warner-Lambert v. Apotex established crucial limits on how Hatch-Waxman method-of-use patents can be used to block generic entry. By holding that an ANDA filing is not an act of infringement of a method-of-use patent covering an unapproved indication, and that generic manufacturers do not induce infringement by selling a drug that might be used off-label, the court preserved the ability of generic companies to enter the market for approved drug uses without being held hostage to patents on unapproved uses.
The decision enabled the practice of “skinny labeling” — in which generic manufacturers carve out patented indications from their labels, obtaining approval only for non-patented uses. This practice became a significant mechanism for generic entry and is particularly important for drugs that have both patented and non-patented uses. The case remains the foundational precedent for the limits of § 271(e)(2) infringement and induced infringement in the off-label use context, and its legacy was extensively analyzed in subsequent cases including GSK v. Teva (2021).